Q-omics provides the consensus-scored MIR4456 profile across patient tissues and cancer cell-line models. MIR4456 expression is associated with patient survival in 3 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MIR4456 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, MIR4456 RNA expression shows 1,067 significant gene co-expression associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, KIRC, and STAD as cancer lineages where MIR4456 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4456 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4456 survival associations across molecular data types. MIR4456 RNA expression shows survival associations in the most cancer types (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4456 RNA expression–survival associations across cancer types. High MIR4456 expression shows unfavorable associations in KICH, READ and LUSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MIR4456 RNA expression.
This table summarizes MIR4456 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4456. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4456 shows lower tumor expression in KIRC, KICH and KIRP. The KIRC box plot shows higher MIR4456 RNA expression in normal versus tumor tissue (log2 FC = −0.800, t-test p < 0.001).
This table shows molecular features associated with MIR4456 in patient tissues and cancer cell lines. In patient samples, MIR4456 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
